David Lebowitz
Stock Analyst at Citigroup
(3.25)
# 1,059
Out of 4,761 analysts
106
Total ratings
52.63%
Success rate
0.8%
Average return
Main Sectors:
Stocks Rated by David Lebowitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BBIO BridgeBio Pharma | Maintains: Buy | $45 → $49 | $36.85 | +32.97% | 3 | Feb 21, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $67 → $64 | $32.32 | +98.02% | 12 | Feb 20, 2025 | |
| EXEL Exelixis | Maintains: Buy | $38 → $45 | $36.85 | +22.12% | 2 | Feb 12, 2025 | |
| PTCT PTC Therapeutics | Maintains: Sell | $32 → $45 | $50.69 | -11.23% | 4 | Feb 12, 2025 | |
| INCY Incyte | Maintains: Buy | $97 → $88 | $72.11 | +22.04% | 5 | Feb 11, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Neutral | $44 → $4 | $3.08 | +29.87% | 5 | Feb 10, 2025 | |
| VKTX Viking Therapeutics | Initiates: Neutral | $38 | $34.07 | +11.54% | 1 | Feb 7, 2025 | |
| CYTK Cytokinetics | Initiates: Buy | $86 | $50.26 | +71.11% | 1 | Feb 7, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $65 → $68 | $52.45 | +29.65% | 4 | Nov 13, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $25 → $19 | $12.17 | +56.12% | 6 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $22.46 | +211.67% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $8.00 | +87.50% | 3 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $178 → $207 | $152.43 | +35.80% | 12 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $65 → $76 | $92.25 | -17.62% | 5 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $39 → $37 | $22.64 | +63.43% | 9 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $382 | $336.23 | +13.61% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $103 → $96 | $68.25 | +40.66% | 3 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $12 | $1.76 | +581.82% | 2 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $170 → $164 | $250.59 | -34.55% | 7 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $39 | $13.02 | +199.54% | 6 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $21 | $16.38 | +28.21% | 11 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $29 → $27 | $0.60 | +4,412.03% | 1 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $13 → $14 | $1.82 | +671.35% | 2 | Oct 12, 2021 |
BridgeBio Pharma
Feb 21, 2025
Maintains: Buy
Price Target: $45 → $49
Current: $36.85
Upside: +32.97%
Ionis Pharmaceuticals
Feb 20, 2025
Maintains: Buy
Price Target: $67 → $64
Current: $32.32
Upside: +98.02%
Exelixis
Feb 12, 2025
Maintains: Buy
Price Target: $38 → $45
Current: $36.85
Upside: +22.12%
PTC Therapeutics
Feb 12, 2025
Maintains: Sell
Price Target: $32 → $45
Current: $50.69
Upside: -11.23%
Incyte
Feb 11, 2025
Maintains: Buy
Price Target: $97 → $88
Current: $72.11
Upside: +22.04%
Pliant Therapeutics
Feb 10, 2025
Downgrades: Neutral
Price Target: $44 → $4
Current: $3.08
Upside: +29.87%
Viking Therapeutics
Feb 7, 2025
Initiates: Neutral
Price Target: $38
Current: $34.07
Upside: +11.54%
Cytokinetics
Feb 7, 2025
Initiates: Buy
Price Target: $86
Current: $50.26
Upside: +71.11%
Mirum Pharmaceuticals
Nov 13, 2024
Maintains: Buy
Price Target: $65 → $68
Current: $52.45
Upside: +29.65%
Intellia Therapeutics
Oct 25, 2024
Maintains: Neutral
Price Target: $25 → $19
Current: $12.17
Upside: +56.12%
Oct 7, 2024
Initiates: Buy
Price Target: $70
Current: $22.46
Upside: +211.67%
Sep 24, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $8.00
Upside: +87.50%
Sep 17, 2024
Maintains: Buy
Price Target: $178 → $207
Current: $152.43
Upside: +35.80%
May 3, 2024
Maintains: Sell
Price Target: $65 → $76
Current: $92.25
Upside: -17.62%
May 2, 2024
Maintains: Buy
Price Target: $39 → $37
Current: $22.64
Upside: +63.43%
Mar 6, 2024
Initiates: Buy
Price Target: $382
Current: $336.23
Upside: +13.61%
Jun 30, 2023
Maintains: Neutral
Price Target: $103 → $96
Current: $68.25
Upside: +40.66%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $18 → $12
Current: $1.76
Upside: +581.82%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $170 → $164
Current: $250.59
Upside: -34.55%
Jun 7, 2022
Maintains: Overweight
Price Target: $36 → $39
Current: $13.02
Upside: +199.54%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $20 → $21
Current: $16.38
Upside: +28.21%
Oct 12, 2021
Maintains: Overweight
Price Target: $29 → $27
Current: $0.60
Upside: +4,412.03%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $13 → $14
Current: $1.82
Upside: +671.35%